secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2026-11-06T22:25:10+00:00
Accession:  0001493152-26-050532
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 4.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Shuttle Pharmaceuticals engages Bush & Associates as new auditor, replacing Forvis Mazars
--------------------------------------------------------------------------------

- Audit Committee and full Board approved dismissal of Forvis Mazars, LLP, effective after filing of the Form 10-Q for the quarter ended September 30, 2026.
- Bush & Associates CPA LLC engaged November 2, 2026 under an engagement letter dated October 19, 2026; Audit Committee approved in October 2026.
- New auditor will audit FY ending December 31, 2026 financials and review interim quarters ending March 31, June 30 and September 30, 2027.
- Company reports no disagreements with Forvis Mazars and no reportable events under Item 304(a)(1)(iv)/(v); no consultations with Bush & Associates in FY2024-2025 or interim period.
- Signed by Christopher Cooper, Co-Chief Executive Officer, and dated November 6, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226050532/0001493152-26-050532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226050532/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer